PTC Therapeutics Q4 2023 Adj EPS $(0.240) Misses $0.500 Estimate, Sales $307.056M Miss $321.294M Estimate
Portfolio Pulse from Benzinga Newsdesk
PTC Therapeutics (NASDAQ:PTCT) reported Q4 2023 adjusted EPS of $(0.240), missing the $0.500 estimate, and sales of $307.056M, missing the $321.294M estimate. This represents an 83.41% increase in sales compared to the same period last year.
February 29, 2024 | 9:24 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
PTC Therapeutics reported a significant miss in both adjusted EPS and sales for Q4 2023, with adjusted EPS missing the estimate by 148% and sales missing by 4.43%, despite an 83.41% increase in sales YOY.
Missing both EPS and sales estimates significantly, especially with a 148% miss on the EPS estimate, is likely to negatively impact investor sentiment and stock price in the short term. The increase in sales YOY, although positive, may not be enough to offset the negative impact of the earnings miss.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100